Obesity drugs #
Trial-level efficacy, sales, forward calendar, and full pipelines across the seven sponsors racing for GLP-1, amylin, and combination obesity drugs.
(Retatrutide, TRIUMPH-1)
(Q2 2026)
Approval status #
Where every tracked obesity drug stands with regulators, when the approved ones were cleared, and the next scheduled milestone for each. As of 2026-08-06.
| Drug | Sponsor | Status | First approved | Next regulatory milestone |
|---|---|---|---|---|
| FoundayoOrforglipron | Eli Lilly | Approved | FDA 1 Apr 2026 | None scheduled |
| Mazdutide | Innovent Biologics | Approved | NMPA (China) 27 Jun 2025 | None scheduled |
| WegovySemaglutide | Novo Nordisk | Approved | FDA 4 Jun 2021 | None scheduled |
| Wegovy HDSemaglutide | Novo Nordisk | Approved | FDA 19 Mar 2026 | None scheduled |
| Wegovy pillSemaglutide | Novo Nordisk | Approved | FDA 22 Dec 2025 | None scheduled |
| ZepboundTirzepatide | Eli Lilly | Approved | FDA 8 Nov 2023 | None scheduled |
| CagriSema | Novo Nordisk | Filed, awaiting decision | Not approved | CagriSema FDA decision (PDUFA) ~Oct 2026 |
| Cagrilintide | Novo Nordisk | Phase 3 | Not approved | None scheduled |
| Ecnoglutide | Sciwind Biosciences | Phase 3 | Not approved | None scheduled |
| Retatrutide | Eli Lilly | Phase 3 | Not approved | Retatrutide FDA submission (Obesity + OA + OSA) Q1 2027 |
| Survodutide | Boehringer Ingelheim | Phase 3 | Not approved | Survodutide regulatory submission (obesity) Q4 2026 |
| Aleniglipron | Structure Therapeutics | Phase 2 | Not approved | None scheduled |
| Berobenatide | Pfizer | Phase 2 | Not approved | None scheduled |
| Elecoglipron | AstraZeneca | Phase 2 | Not approved | None scheduled |
| Eloralintide | Eli Lilly | Phase 2 | Not approved | None scheduled |
| Enicepatide | Roche | Phase 2 | Not approved | None scheduled |
| MariTideMaridebart cafraglutide | Amgen | Phase 2 | Not approved | None scheduled |
| Petrelintide | Roche | Phase 2 | Not approved | None scheduled |
| UBT251 | Novo Nordisk | Phase 2 | Not approved | None scheduled |
| VK2735 | Viking Therapeutics | Phase 2 | Not approved | None scheduled |
| Zenagamtide | Novo Nordisk | Phase 2 | Not approved | None scheduled |
| Danuglipron | Pfizer | Discontinued | Not approved | None scheduled |
Compare drugs
Weight-loss trajectories, efficacy vs tolerability, and a sortable data table - one filter and estimand toggle across every obesity drug.
Open the explorer →Pipeline & indications
Every disclosed asset by sponsor and phase, plus the beyond-weight-loss indication matrix (CV, MASH, CKD, OSA, HFpEF).
See the pipeline →Sales
Quarterly revenue per obesity SKU in EUR - how the commercial race between Wegovy, Zepbound, and the oral entrants tracks.
View sales →Calendar
Forward catalysts - earnings, trial readouts, and FDA decisions - ordered by date and tiered by stock impact.
See the calendar →Drug profiles A–Z
In-depth profile page for every drug we track - weight-loss trajectory, dosing, mechanism, and trial detail.
- AleniglipronStructure Therapeutics
- BerobenatidePfizer
- CagrilintideNovo Nordisk
- CagriSemaNovo Nordisk
- DanuglipronPfizer
- EcnoglutideSciwind Biosciences
- ElecoglipronAstraZeneca
- EloralintideEli Lilly
- EnicepatideRoche
- Maridebart cafraglutideAmgen
- MazdutideInnovent Biologics
- OrforglipronEli Lilly
- PetrelintideRoche
- RetatrutideEli Lilly
- SemaglutideNovo Nordisk
- SurvodutideBoehringer Ingelheim
- TirzepatideEli Lilly
- UBT251Novo Nordisk
- VK2735Viking Therapeutics
- ZenagamtideNovo Nordisk
The companies behind them
Financials, valuation and estimates for each sponsor with an obesity asset in the table above.
- Novo Nordisk 7 assets
- Eli Lilly 4 assets
- Pfizer 2 assets
- Amgen 1 asset
- AstraZeneca 1 asset
- Viking Therapeutics 1 asset
Latest blog: The GLP-1 Race Splits in Two: Novo and Lilly After Q2 2026 (2026-08-08) · more posts tagged obesity